Ratika Srivastava
Address: Department of Microbiology & Biotechnology Center,
Faculty of Science, Maharaja Sayajirao University of Baroda, Vadodara, Gujarat
Email Address: srivastava.ratika@gmail.com
1 Present Position
Assistant Professor- UGC (January, 2016 onwards), Department of Microbiology &
Biotechnology Center, Maharaja Sayajirao University of Baroda, Vadodara, Gujarat
[Selected through University Grant Commission Faculty Recharge Programme (FRP)]
2 Professional Experience
Principal Investigator (April, 2015- August, 2015)
Senior Research Investigator (December, 2011-March, 2015)
Biocon Bristol Myers Squibb Research Center (BBRC), Bangalore, India
Postdoctoral Experience (June, 2009 to December, 2011)
i) Postdoctoral Fellow at Marlene and Stewart Greenebaum Cancer Center, University of
Maryland, Baltimore, Maryland, USA
Research Area: T cell based melanoma therapy, IRAK inhibitors as melanoma therapy
ii) Postdoctoral Researcher at Stanley S Scott Cancer Center, Louisiana State University Health
Science Center, New Orleans, Louisiana, USA
Research Area: Study TLR agonist as adjuvant in T cell based melanoma therapy, role
of TNF family costimulatory molecules in cytotoxic activity
iii) Postdoctoral Fellow at University of Cincinnati, Cincinnati, Ohio, USA
Research Area: Role of Interferon inducible gene in lupus progression
3 Academic qualifications
A) Ph.D.
Title: Role of immune responses in pathogenesis of acute hepatitis E
Affiliation: Department of Immunology, Sanjay Gandhi Post Graduate Institute of Medical
Sciences, Lucknow, India.
B) Master of Science (M.Sc.)
Institute: V.B.S. Purvanchal University, Jaunpur, U.P., India
Discipline: Bio-technology
C) Bachelor of Science (B.Sc.)
Institute: Isabella Thoburn College (Lucknow University), Lucknow, India
Subjects: Zoology, Botany and Chemistry
4 Research Interests: Cancer Immunotherapy, Autoimmunity
5 Publications
1. Therapeutic potential of chloroquine in a murine model of inflammatory bowel disease.
Nagar J, Ranade S, Kamath V, Singh S, Karunanithi P, Subramani S, Venkatesh K,
Srivastava R, Dudhgaonkar S, Vikramadithyan RK. Int Immunopharmacol. 2014
Aug;21(2):328-35.
2. Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4.
Srivastava R, Geng D, Liu Y, Zheng L, Li Z, Joseph MA, McKenna C, Bansal N, Ochoa
A, Davila E. Cancer Res. 2012 Dec 1;72(23):6209-16.
3. Redirecting gene-modified T cells toward various cancer types using tagged antibodies.
Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, Davila E. Clin. Cancer
Res. 2012 Dec 1;18(23):6436-45.
4. Evidence of hepatitis E virus exposure among seronegative healthy residents of an
endemic area. Husain MM., Srivastava R., Akondy R., Aggarwal R., Jameel S., Naik S.
Intervirology. 2010 Oct 21;54(3):139-143.
5. Amplifying TLR-MyD88 signals within tumor-specific T-cells enhances antitumor activity
to suboptimal levels of weakly-immunogenic tumor-antigens. Geng D, Zheng L,
Srivastava R, Riker AI, Velasco-Gonzales C, Markovic SN, Davila E. Cancer Res. 2010
Oct 1;70(19):7442-54.
6. When toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced
CD8 T-cell effectors function. Geng D, Zheng L, Srivastava R, Asprodites N, VelascoGonzalez C, Davila E. Blood. 2010 Aug 9.
7. Adaptive immune responses during acute uncomplicated and fulminant hepatitis E.
Ratika Srivastava, Rakesh Aggarwal, Sanjeev Sachdeva, Mohammad Intakhab Alam,
Shahid Jameel, Sita Naik. J Gastroenterol Hepatol. 2011 Feb;26(2):306-11.
8. Interferon-inducible p200-family proteins as novel sensors of cytoplasmic DNA: role in
inflammation and autoimmunity. Choubey D, Duan X, Dickerson E, Ponomareva L,
Panchanathan R, Shen H, Srivastava R. J Interferon Cytokine Res. 2010 Jun;30(6):37180.
9. Alterations in natural killer cells and natural killer T cells during acute viral hepatitis E.
Srivastava R, Aggarwal R, Bhagat MR, Chowdhury A, Naik S.J Viral Hepat. 2008
Dec;15(12):910-6.